SOST and prostate cancer: Sost, an osteocyte-derived Wnt inhibitor, was found to be deregulated in osteoblasts in an in vitro model of osteoblasts-prostate cancer interactions, and that Sost acted as major regulator of gene expression in highly invasive PC3 cells.